|
When pancreatic insufficiency is thought to
be a contributing factor to malabsorption,
ULTRASE® / ULTRASE® MT (pancrelipase) may
be prescribed to deliver bioactive enzymes
to the site of digestion and provide relief from
steatorrhea-related diarrhea.
ULTRASE® / ULTRASE® MT Capsules provide:
- Relief from steatorrhea1
- Bioactive enzymes specially formulated
for delivery to the site of digestion1
- Brand quality, competitively priced2
If your clinician has specified "Dispense as
Written" on your prescription for ULTRASE® / ULTRASE® MT, it is to ensure that you get the
proven and complete pancreatic enzyme and not a
potentially non-bioequivalent alternate pancreatic
enzyme product.
Comprehensive patient support
- Comprehensive financial and educational
support programs form a complete package
to meet the needs of patients
and their families.
No approved generic equivalents
- Pancreatic enzyme products have not
been determined to be bioequivalent
(i.e., all are not the same). Bioavailability
of these products is dependent on the
formulation and process used to
manufacture them.3
Excellent safety and efficacy profile4,5
- Up to 71% dietary protein absorption improvement vs. placebo
- Up to 67% dietary fat absorption improvement vs. placebo
- Fewer adverse events vs. placebo
- Most dosing options for ease-of-titration
Proven symptomatic relief4
- Up to 67% of patients experienced
abdominal pain relief
- Up to 42% of patients
from flatulence
REFERENCES: 1. ULTRASE® MT (pancrelipase) Capsules Prescribing Information 2. 2005
Red Book. 3. Hendeles, L. Letters to the editor: unapproved generic pancreatic enzymes. J Pediatr
Pharmacol Ther 2001; 6:10-11. 4. Konstan M et al. ULTRASE® and ULTRASE® MT20 in the
treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy. Aliment Pharmacol
Ther 2004; 20:1365-1371. 5. Data on file, Axcan Scandipharm Inc., 2003.
|
Rx CompleteSM
